CBFβ-SMMHC, expressed in M4eo acute myeloid leukemia, reduces p53 induction and slows apoptosis in hematopoietic cells exposed to DNA-damaging agents

Blood

Volumn 92, Issue 11, 1998, Pages 4344-4352

  Britos Bray, Martin ^b   Ramirez, Manuel ^b   Cao, Wangsen ^b   Wang, Xinping ^b   Liu, P Paul ^b   Civin, Curt I ^b   Friedman, Alan D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; ANTINEOPLASTIC AGENT; CBFBETA MYH11 FUSION PROTEIN; CBFBETA-MYH11 FUSION PROTEIN; ETOPOSIDE; ONCOPROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL MODEL; APOPTOSIS; ARTICLE; CHROMOSOME 16; CHROMOSOME INVERSION; CONTROLLED STUDY; DNA DAMAGE; HEMATOPOIETIC CELL; LEUKEMOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; ACUTE DISEASE; CELL CULTURE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MYELOID LEUKEMIA; PATHOLOGY; RADIATION EXPOSURE;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; DNA DAMAGE; ETOPOSIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOID; ONCOGENE PROTEINS, FUSION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032217051     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.11.4344     Document Type: Article

References (51)

1. Arthur DC, Bloomfield CD: Partial deletion of the long arm of chromosome 16 and bone marrow eosinophilia in acute nonlymphocytic leukemia, a new association. Blood 61:994, 1983
2. Le Beau MM, Larson RA, Bitter MA, Vardiman JW, Golomb HM, Rowley JD: Association of inversion of chromosome 16 with abnormal marrow eosinophils in acute myeloid leukemia. N Engl J Med 309:630, 1983
3. Liu PP, Tarle SA, Hajre A, Claxton DF, Marlton P, Freedman M, Siciliano MJ, Collins FS: Fusion between transcription factor CBFβ/PEBP2β and a myosin heavy chain in acute myeloid leukemia. Science 261:1041, 1993
4. Liu PP, Wijmenga C, Hajra A, Blake TB, Kelley CA, Adelstein RS, Bagg A, Rector J, Cotelingam J, Willman CL, Collins FS: Identification of the chimeric protein product of the CBFB-MYH11 fusion gene in inv(16) leukemia cells. Genes Chromosomes Cancer 16:77, 1996
5. Bae SC, Yamaguchi-Iwai Y, Ogawa E, Maruyama M, Inuzuka M, Kagoshima H, Shigesada K, Satake M, Ito Y: Isolation of PEBP2αB cDNA representing the mouse homolog of human acute myeloid leukemia gene, AML1. Oncogene 8:809, 1993
6. Ogawa E, Maruyama M, Kagoshima H, Inuzuka M, Lu J, Satake M, Shigesada K, Ito Y: PEBP2/PEA2 represents a family of transcription factors homologous to the products of the Drosophila runt gene and the human AML1 gene. Proc Natl Acad Sci USA 90:6859, 1993
7. Ogawa E, Inuzuka M, Maruyamna M, Satake M, Naito-Fujimoto M, Ito Y, Shigesada K: Molecular cloning and characterization of PEBP2β, the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2α. Virology 194:314, 1993
8. Wang S, Wang Q, Crute BE, Melnikova IN, Keller SR, Speck NA: Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor. Mol Cell Biol 13:3324, 1993
9. Levanon D, Negreanu V, Bernstein Y, Bar-Am I, Avivi L, Groner Y: AML1, 2 and 3. The human members of the runt domain gene-family. Genomics 23:425, 1994
10. Meyers S, Downing JR, Hiebert SW: Identification of AML1 and the (8;21) translocation protein AML1-ETO as sequence specific DNA binding proteins: The runt homology domain is required for DNA binding and protein-protein interactions. Mol Cell Biol 13:6336, 1993
11. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR: AML-1, the target of multiple chromosomal translocations in human leukemia, is essential for normal murine fetal liver hematopoiesis. Cell 84:321, 1996
12. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA: Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci USA 93:3444, 1996
13. Wang Q, Stacy T, Miller JD, Lewis AF, Gu T-L, Huang X, Bushweller JH, Bories J-C, Alt FW, Ryan G, Liu PP, Wynshaw-Boris A, Binder M, Marin-Padilla M, Sharpe AH, Speck NA: The CBF β subunit is essential for CBFα2 (AML1) function in vivo. Cell 87:697, 1996
14. Sasaki K, Yagi H, Bronson RT, Tominaga K, Matsunashi T, Deguchi K, Tani Y, Kishimoto T, Komori T: Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor β. Proc Natl Acad Sci USA 93:12359, 1996
15. Adelstein RS, Sellers JR: Myosin structure and function, in Barany M (ed): Biochemistry of Smooth Muscle Contraction. New York, NY, Academic, 1996, p 3
16. Wijmenga C, Gregory PE, Hajra A, Schrock E, Ried T, Eils T, Liu PP, Collins FS: CBFβ-SMMHC chimeric protein involved in AML forms unusual nuclear rod-like structures in transformed NIH 3T3 cells. Proc Natl Acad Sci USA 93:1630, 1996
17. Adya N, Stacy T, Speck NA, Liu PP: The leukemic protein CBFβ-SMMHC sequesters CBFα2 into cytoskeletal filaments and aggregates. Mol Cell Biol (in press)
18. Castilla LH, Wijmenga C, Stacy T, Speck NA, Eckhaus M, Marin-Padilla M, Collins FS, Wynshaw-Boris A, Liu PP: Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11. Cell 87:687, 1996
19. Meyers S, Lenny N, Hiebert SW: The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol Cell Biol 15:1974, 1995
20. Frank R, Zhang J, Uchida H, Meyers S, Hiebert SW, Nimer SD: The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene 11:2667, 1995
21. Hiebert SW, Sun W, Davis JN, Golub T, Shurtleff S, Buijs A, Downing JR, Grosveld G, Roussel MF, Gilliland DG, Lenny N, Meyers S: The t(12;21) translocation converts AML1-1B from an activator to a repressor of transcription. Mol Cell Biol 16:1349, 1996
22. Yergeau DA, Hetherington CJ, Wang Q, Zhang P, Sharpe AH, Binder M, Marin-Padilla M, Tenen DG, Speck NA, Zhang D-E: Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet 15:303, 1997
23. Okuda T, Cai Z, Yang S, Lenny N, Lyu C-J, van Deursen JMA, Harada H, Downing JR: Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood 91:3134, 1998
24. Cao W, Britos-Bray M, Claxton DF, Kelley CA, Speck NA, Liu PP, Friedman AD: CBFβ-SMMHC, expressed in M4eo AML, reduced CBF DNA-binding and inhibited the G1 to S cell cycle transition at the restriction point in myeloid and lymphoid cells. Oncogene 15:1315, 1997
25. Nuchprayoon I, Meyers S, Scott LM, Suzow J, Hiebert S, Friedman AD: PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2β/CBFβ oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells. Mol Cell Biol 14:5558, 1994
26. Imamura J, Miyoshi I, Koeffler P: p53 in hematologic malignancies. Blood 84:2412, 1994
27. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304, 1991
28. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957, 1993
29. Nelson WG, Kastan MB: DNA strand breaks: The DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14:1815, 1994
30. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379:88, 1996
31. Canman CE, Gilmer TM, Coutts SB, Kastan MB: Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev 9:600, 1995
32. Lowe SW, Schmitt SW, Smith SW, Osborne BA, Jacks T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847, 1993
33. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wylie AH: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849, 1993
34. Polyak K, Waldman T, He T-C, Kinzler KW, Vogelstein B: Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 10:1945, 1996
35. Scott LM, Civin CI, Rorth P, Friedman AD: A novel temporal expression pattern of three C/EBP family members in differentiating myelomonocytic cells. Blood 80:1725, 1992
36. Cameron S, Taylor DS, TePas EC, Speck NA, Mathey-Prevot B: Identification of a critical regulatory site in the human interleukin-3 promoter by in vivo footprinting. Blood 83:2851, 1993
37. Martin SJ, Finucane DM, Amarante-Mendes GP, O'Brien GA, Green DR: Phosphatidylserine externalization during CD95-induced apoptosis of cells and cytoplasts required ICE/CED-3 protease activity. J Biol Chem 271:28753, 1996
38. Vanags DM, Porn-Ares MI, Coppola S, Burgress DH, Orrenius S: Protease involvement in fodrin cleavage and phosphatidylserine exposure in apoptosis. J Biol Chem 271:31075, 1996
39. Reed JC, Miyashita T, Takayama S, Wang H-G, Sato T, Krajewski S, Aime-Sempe C, Bodrug S, Kitada S, Hanada M: BCL-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to chemotherapy. J Cell Biochem 60:23, 1996
40. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293, 1995
41. Cao W, Adya N, Britos-Bray M, Liu PP, Friedman AD: The core binding factor α interaction domain and the smooth muscle myosin heavy chain segment of CBFβ-SMMHC are both required to slow cell proliferation. J Biol Chem (in press)
42. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M: Wild-type p53 induces apoptosis of myeloid leukemia cells that is inhibited by interleukin-6. Nature 352:345, 1991
43. Canman CE, Kastan MB: Small contribution of G1 checkpoint control manipulation to modulation of p53-mediated apoptosis. Oncogene 16:957, 1998
44. Palayoor ST, Macklis RM, Bump EA, Coleman N: Modulation of radiation-induced apoptosis and G2/M block in murine T-lymphoma cells. Radiat Res 141:235, 1995
45. Nishii K, Kabarowski JHS, Gibbons DL, Griffiths SD, Titley I, Wiedemann LM, Greaves MF: tsBCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. Oncogene 13:2225, 1996
46. Bedi A, Barber JP, Bedi GC, El-Diery WS, Sidransky D, Vala MS, Akhtar AJ, Hilton J, Jones RJ: BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents. Blood 86:1148, 1995
47. Samuels BL, Larson RA, Le Beau MM, Daly KM, Bitter MA, Vardiman JW, Barker CM, Rowley JD, Golomb HM: Specific chromosomal abnormalities in AML correlate with drug susceptibility in vivo. Leukemia 2:79, 1988
48. Bienz-Tadmor B, Zakut-Houri R, Libresco S, Givol D, Oren M: The 5′ region of the p53 gene: Evolutionary conservation and evidence for a negative regulatory element. EMBO J 4:3209, 1985
49. Haupt Y, Ruth M, Kazaz A, Oren M: Mdm2 promotes the rapid degradation of p53. Nature 387:296, 1997
50. Kubbutat MH, Jones SN, Vousden KH: Regulation of p53 stability by Mdm2. Nature 387:299, 1997
51. Siliciano JD, Canman CE, Taya T, Sakaguchi K, Appella E, Kastan MB: DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 11:3471, 1997